Avanos Medical (NYSE:AVNS) Cut to “Strong Sell” at Zacks Research

Zacks Research lowered shares of Avanos Medical (NYSE:AVNS) from a hold rating to a strong sell rating in a research report released on Monday morning,Zacks.com reports. Zacks Research also issued estimates for Avanos Medical’s Q4 2025 earnings at $0.24 EPS, FY2025 earnings at $0.89 EPS, Q1 2026 earnings at $0.23 EPS, Q2 2026 earnings at $0.22 EPS, Q3 2026 earnings at $0.27 EPS, Q4 2026 earnings at $0.36 EPS, FY2026 earnings at $1.08 EPS, Q1 2027 earnings at $0.33 EPS, Q2 2027 earnings at $0.32 EPS, Q3 2027 earnings at $0.26 EPS and FY2027 earnings at $1.24 EPS.

A number of other research analysts have also issued reports on the company. Weiss Ratings reiterated a “sell (d)” rating on shares of Avanos Medical in a research report on Monday. Wall Street Zen upgraded shares of Avanos Medical from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Two analysts have rated the stock with a Sell rating, According to MarketBeat, the stock has a consensus rating of “Sell”.

Avanos Medical Trading Down 0.5%

Avanos Medical stock opened at $11.30 on Monday. Avanos Medical has a 52-week low of $9.30 and a 52-week high of $19.29. The company has a quick ratio of 1.36, a current ratio of 2.38 and a debt-to-equity ratio of 0.12. The firm has a market capitalization of $524.31 million, a price-to-earnings ratio of -1.11 and a beta of 1.09. The firm has a 50-day moving average price of $11.44 and a two-hundred day moving average price of $11.78.

Avanos Medical (NYSE:AVNS) last released its quarterly earnings results on Wednesday, November 5th. The company reported $0.22 earnings per share for the quarter, beating analysts’ consensus estimates of $0.12 by $0.10. The company had revenue of $177.80 million for the quarter, compared to analysts’ expectations of $164.50 million. Avanos Medical had a positive return on equity of 6.21% and a negative net margin of 67.00%.The business’s revenue for the quarter was up 4.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.33 earnings per share. Avanos Medical has set its FY 2025 guidance at 0.850-0.950 EPS. Sell-side analysts expect that Avanos Medical will post 1.32 earnings per share for the current year.

Insider Transactions at Avanos Medical

In other Avanos Medical news, SVP Kerr Holbrook sold 15,000 shares of the business’s stock in a transaction dated Tuesday, November 18th. The shares were sold at an average price of $11.00, for a total value of $165,000.00. Following the sale, the senior vice president directly owned 83,860 shares in the company, valued at approximately $922,460. The trade was a 15.17% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 2.64% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Avanos Medical

Several hedge funds have recently made changes to their positions in the business. Armistice Capital LLC raised its holdings in shares of Avanos Medical by 22.8% in the 3rd quarter. Armistice Capital LLC now owns 2,500,000 shares of the company’s stock worth $28,900,000 after purchasing an additional 464,000 shares in the last quarter. Wexford Capital LP acquired a new position in Avanos Medical in the third quarter worth approximately $70,000. Quantessence Capital LLC bought a new position in shares of Avanos Medical in the third quarter valued at $116,000. Qube Research & Technologies Ltd lifted its position in shares of Avanos Medical by 16.4% during the 3rd quarter. Qube Research & Technologies Ltd now owns 727,838 shares of the company’s stock valued at $8,414,000 after acquiring an additional 102,429 shares during the last quarter. Finally, Numerai GP LLC bought a new stake in shares of Avanos Medical during the 3rd quarter worth $1,374,000. Institutional investors and hedge funds own 95.17% of the company’s stock.

About Avanos Medical

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.